Literature DB >> 19000959

Impact of patient-general practitioner short-messages-based interaction on the control of hypertension in a follow-up service for low-to-medium risk hypertensive patients: a randomized controlled trial.

Mario Pascual Carrasco1, Carlos H Salvador, Pilar G Sagredo, Joaquín Márquez-Montes, Miguel A González de Mingo, Juan A Fragua, Montserrat Carmona Rodríguez, Luis M García-Olmos, Fernando García-López, Adolfo Muñoz Carrero, Jose L Monteagudo.   

Abstract

The evaluation in real-life settings of services for the follow-up and control of hypertensive patients is a complex intervention, which still needs analysis of the roles, tasks, and resources involved in the basic items: patient, healthcare professional, and the interaction between the two. To evaluate the impact of patient-general practitioner (GP) short-messages-based interaction, isolated from other items, on the degree of hypertension control in the follow-up of medium-to-low-risk patients in primary care, a randomized controlled trial has been performed: 38 GPs enrolled 285 hypertensive patients who recorded the results of self-blood-pressure (BP) monitoring, heart rate, and body weight, and completed an optional questionnaire in an identical manner over a six-month period. The telemedicine group (TmG) sent the data to a telemedicine-based system that enabled patient-GP interaction; the control group (CG) recorded the data on paper and could only deliver it to their GP personally in the routine visits. In the TmG, the results were better, but not significantly so, for: 1) degree of hypertension control, in terms of the percentage of uncontrolled hypertensives at the final visit (TmG versus CG: 31.7% versus 35.6%; p = 0.47); 2) reduction in hypertension during follow-up, comparing measurements (performed by a professional) at the initial and final visits of systolic BP (15.5 versus 11.9; p = 0.13) and diastolic BP (9.6 versus 4.4; p = 0.40); and 3) adherence to the protocol within compliance levels of interest in a real-life follow-up service: >>50% (84.8% versus 73.3%) and >>25% (92.4.8% versus 75.4%) ( p = 0.053). Other factors such as average values of self-measured systolic BP, diastolic BP and heart rate, acceptability of the protocol, and median number of consultations and hospital admissions were similar in both groups. Outcomes show that, taken alone, the patient-GP short-messages-based interaction has very little impact on the degree of hypertension control in patients with this profile. In complex interventions, to discriminate the impact of each of its components in isolation will enable us to design an efficient follow-up service, little demanding in terms of healthcare professional dedication, and optimized in other basic aspects.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19000959     DOI: 10.1109/TITB.2008.926429

Source DB:  PubMed          Journal:  IEEE Trans Inf Technol Biomed        ISSN: 1089-7771


  33 in total

1.  Definition of information technology architectures for continuous data management and medical device integration in diabetes.

Authors:  M Elena Hernando; Mario Pascual; Carlos H Salvador; Gema García-Sáez; Agustín Rodríguez-Herrero; Iñaki Martínez-Sarriegui; Enrique J Gómez
Journal:  J Diabetes Sci Technol       Date:  2008-09

Review 2.  Effectiveness of home blood pressure telemonitoring: a systematic review and meta-analysis of randomised controlled studies.

Authors:  Y Duan; Z Xie; F Dong; Z Wu; Z Lin; N Sun; J Xu
Journal:  J Hum Hypertens       Date:  2017-03-23       Impact factor: 3.012

3.  Technology for Behavioral Change in Rural Older Adults with Obesity.

Authors:  John A Batsis; John A Naslund; Alexandra B Zagaria; David Kotz; Rachel Dokko; Stephen J Bartels; Elizabeth Carpenter-Song
Journal:  J Nutr Gerontol Geriatr       Date:  2019-04-11

Review 4.  Use of Short Messaging Service for Hypertension Management: A Systematic Review.

Authors:  Grecia Vargas; Maan Isabella Cajita; Erin Whitehouse; Hae-Ra Han
Journal:  J Cardiovasc Nurs       Date:  2017 May/Jun       Impact factor: 2.083

5.  Implementing home blood glucose and blood pressure telemonitoring in primary care practices for patients with diabetes: lessons learned.

Authors:  Richelle J Koopman; Bonnie J Wakefield; Jennifer L Johanning; Lynn E Keplinger; Robin L Kruse; Marilee Bomar; Beth Bernt; Douglas S Wakefield; David R Mehr
Journal:  Telemed J E Health       Date:  2013-12-18       Impact factor: 3.536

Review 6.  Mobile phone messaging for facilitating self-management of long-term illnesses.

Authors:  Thyra de Jongh; Ipek Gurol-Urganci; Vlasta Vodopivec-Jamsek; Josip Car; Rifat Atun
Journal:  Cochrane Database Syst Rev       Date:  2012-12-12

Review 7.  Mobile phone messaging for preventive health care.

Authors:  Vlasta Vodopivec-Jamsek; Thyra de Jongh; Ipek Gurol-Urganci; Rifat Atun; Josip Car
Journal:  Cochrane Database Syst Rev       Date:  2012-12-12

Review 8.  The effectiveness of mobile-health technology-based health behaviour change or disease management interventions for health care consumers: a systematic review.

Authors:  Caroline Free; Gemma Phillips; Leandro Galli; Louise Watson; Lambert Felix; Phil Edwards; Vikram Patel; Andy Haines
Journal:  PLoS Med       Date:  2013-01-15       Impact factor: 11.069

9.  Mobile Phone Text Messages to Support Treatment Adherence in Adults With High Blood Pressure (SMS-Text Adherence Support [StAR]): A Single-Blind, Randomized Trial.

Authors:  Kirsten Bobrow; Andrew J Farmer; David Springer; Milensu Shanyinde; Ly-Mee Yu; Thomas Brennan; Brian Rayner; Mosedi Namane; Krisela Steyn; Lionel Tarassenko; Naomi Levitt
Journal:  Circulation       Date:  2016-01-14       Impact factor: 29.690

10.  A texting-based blood pressure surveillance intervention.

Authors:  Roula S Zahr; Chris A Anthony; Philip M Polgreen; Jacob E Simmering; Christopher J Goerdt; Angela B Hoth; Michelle L Miller; Manish Suneja; Alberto M Segre; Barry L Carter; Joseph E Cavanaugh; Linnea A Polgreen
Journal:  J Clin Hypertens (Greenwich)       Date:  2019-09-10       Impact factor: 3.738

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.